An experimental vaccine developed by the National Institute of Health and Moderna Inc will start the final testing phase in the U.S. beginning with 30,000 people on July 27th.
The testing will be a key phase in the road to a vaccine against COVID-19.
“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press.
Fauci’s colleagues at the Institute are the developers behind the would be vaccine. The phase is being entered following a testing of 45 volunteers, who submitted to testing in March. The goal of the vaccine is to offer an immune boost against the pandemic.
There are no guarantees to the virus, but it would require two doses, set two months apart to administer.
Side effects were reported with the drug with over half of participants reporting reactions uncommon to other vaccines, including fatigue, headache, chills, fever and pain at the injection site.
